Clinical trials
Nasopharyngeal Carcinoma clinical trials
Below are recruiting nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 162 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05772208RecruitingPhase 3
New treatment plan for nasopharyngeal cancer after EBV DNA stays detectable
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT07362979RecruitingPhase 2
Toripalimab with chemo for advanced nasopharyngeal cancer
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
Dongguan, GuangdongAges 18–70 - NCT07154069RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer after chemo
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Guangzhou, GuangdongAges 18–65 - NCT06912698RecruitingPhase 3
Lower vs. standard radiation for early nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
Guangzhou, GuangdongAges 18–70 - NCT06688175Enrolling by invitationPhase 2
Combining IMRT and lobaplatin chemo for nasopharyngeal cancer
This trial tests whether combining a newer chemotherapy drug (lobaplatin) with standard radiation and chemotherapy is safe and effective for adults aged 65 to 80 with a certain type of nasopharyngeal cancer that hasn't spread to distant organs.
Xiamen, FujianAges 65–80 - NCT06669611RecruitingPhase 3
Comparing two drug combos for advanced nasopharyngeal cancer
This trial tests whether a new drug combination (Nab-Paclitaxel with Camrelizumab) works better than the standard GP chemotherapy plus Camrelizumab for people whose nasopharyngeal cancer has come back or spread. The goal is to find a more effective treatment option.
Guangzhou, GuangdongAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.
Bethesda, MarylandAges 18–120 - NCT06349889RecruitingPhase 2
Adebrelimab with chemo and radiation for high-risk nasopharyngeal cancer
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation for people with a high-risk type of nasopharyngeal cancer (stage IVA). The goal is to see if this combination helps control the cancer better.
Xiamen, FujianAges 18–65 - NCT07705243RecruitingPhase 3
Maintenance therapy for advanced nasopharyngeal cancer
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Guangzhou, GuangdongAges 18–75 - NCT07528183RecruitingPhase 2
Immunotherapy after chemo and radiation for recurrent nose cancer
This trial tests whether maintenance immunotherapy (PD-1 inhibitor) followed by delayed salvage radiation therapy can help keep your cancer under control after you have already responded to initial chemo-immunotherapy. It is for people with recurrent nasopharyngeal carcinoma that has come back in the nose or neck area, but has not spread to distant organs.
Fuzhou, FujianAges 18–70 - NCT04453826RecruitingPhase 3
Test PD-1 plus chemo-radiation for high-risk nasopharyngeal cancer
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT07796789RecruitingPhase 3
Preventing appetite loss during cancer treatment for nasopharyngeal carcinoma
This trial tests whether a medicine called nanocrystalline megestrol acetate can help prevent loss of appetite caused by chemotherapy and radiation therapy in people with nasopharyngeal carcinoma. If you are receiving chemoradiotherapy for this type of cancer, you may be able to participate.
Guangzhou, GuangdongAges 18–70 - NCT07035626RecruitingPhase 1/Phase 2
Spermidine to prevent dry mouth from radiation therapy
This trial tests whether spermidine (a natural compound) can help prevent dry mouth caused by radiation treatment for head and neck cancer. It is for patients who will receive a significant dose of radiation to their saliva glands.
Chengdu, SichuanAges 18–80 - NCT06829147Recruiting
AI to diagnose lymph node spread in nasopharyngeal cancer
This trial tests whether a computer model can accurately detect if cancer has spread to lymph nodes in patients with nasopharyngeal carcinoma. It uses MRI and PET/CT scans taken before treatment to see if the AI can replace or supplement current methods.
Guangzhou, GuangdongAges Any age - NCT07188584RecruitingPhase 3
Smaller radiation vs. standard after chemo-immunotherapy for advanced nasopharyngeal cancer
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
ZhuhaiAges 18–70 - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT06676722RecruitingPhase 2
SBRT and two targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Xiamen, FujianAges 18–75 - NCT07376603Recruiting
Radiation therapy alone for early-stage nasopharyngeal cancer
This trial tests whether intense radiation therapy (IMRT) alone is effective for people with stage IB nasopharyngeal carcinoma (a type of head and neck cancer) that has not spread to lower lymph nodes or formed large, matted nodes. If you qualify, you would receive targeted radiation without chemotherapy.
Fuzhou, FujianAges 18–70 - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT06831357Recruiting
Predicting Cancer Spread in Nasopharyngeal Cancer Using AI
This trial uses a deep learning computer model to look at tissue images and MRI scans to predict whether nasopharyngeal carcinoma may spread to other parts of the body. It may help doctors decide on the best treatment for people with certain stages of this cancer.
Guangzhou, GuangdongAges Any age - NCT07232680Recruiting
Immune profile study for nasopharyngeal cancer patients
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Taoyuan City, TaiwanAges 18 years+ - NCT06852638RecruitingPhase 2
PET imaging for kidney cancer, lymphoma, and NPC
This study tests a new way to detect tumors by using a special injection that makes cancer cells visible on a PET scan. It may help people with renal cancer (especially clear cell type), lymphoma, or nasopharyngeal cancer.
ShanghaiAges 18–80 - NCT05674305RecruitingPhase 3
Tested radiation alone vs added chemotherapy for EBV-negative after treatment
This Phase 3 trial compares giving radiation alone versus giving radiation at the same time as chemotherapy for nasopharyngeal cancer. It focuses on people whose EBV test becomes undetectable after one cycle of chemotherapy, to see which approach works best and is safest.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 162 recruiting nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Nasopharyngeal Carcinoma (NPC)
- Locally Advanced Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma AJCC v8
- Metastatic Nasopharyngeal Carcinoma
- Stage III Nasopharyngeal Carcinoma AJCC v8
- Nasopharyngeal Carcinoma by AJCC V8 Stage
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.